Close

Business & Industry

METiS TechBio and Eli Lilly Join Forces for Next-Generation Tissue-Specific LNP Delivery Technologies

METiS TechBio has announced a strategic collaboration with Eli Lilly and Company to research and develop next-generation lipid nanoparticle (LNP)-based delivery solutions, leveraging METiS's proprietary AI-driven platform to enable precise, tissue-specific delivery of therapeutic modalities. Under the terms of the...

Eli Lilly and Mubadala Bio Sign Abu Dhabi GLP-1 Packaging Agreement

Eli Lilly and Mubadala Bio have signed a formal agreement to develop local pharmaceutical packaging and logistics capabilities for Lilly's GLP-1 medicines in Abu Dhabi, with the collaboration anchored by a dedicated 125,000 sqm site at Khalifa Economic Zones...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging material carefully designed for non-sterile dry pharmaceutical applications. This newly developed product utilizes fresh fibre featuring tightly controlled purity characteristics to meet rigorous industry demands. As a notable addition to...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership and licensing deal with insitro to identify novel targets and therapies for a range of cardiometabolic diseases. Through this strategic agreement, the organizations will work in tandem to create drugs...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has announced plans to launch its first AI-powered autonomous research facility. Expected to become fully operational in early 2027 at the Abcam headquarters in Cambridge, UK, the upcoming AI autonomous lab...

$1.8 Billion Commitment to Centralize Biological Data

The United States government, alongside technology enterprises Meta Platforms and Alphabet, is officially joining forces with the nonprofit organization Biohub. This collaborative effort aims to construct comprehensive open datasets designed to train advanced AI models for biological research, elevating...

Indiaโ€™s โ‚น2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next Phase of Competition

Indiaโ€™s weight-loss drug story has moved well beyond a niche pharmaceutical category. GLP-1 medicines are now creating a rapidly expanding business around obesity and metabolic health, with Mounjaro and semaglutide at the centre of the competition. Indiaโ€™s GLP-1 segment reached...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป